ES2619322T3 - Agente inductor de inmunidad - Google Patents

Agente inductor de inmunidad Download PDF

Info

Publication number
ES2619322T3
ES2619322T3 ES14185710.2T ES14185710T ES2619322T3 ES 2619322 T3 ES2619322 T3 ES 2619322T3 ES 14185710 T ES14185710 T ES 14185710T ES 2619322 T3 ES2619322 T3 ES 2619322T3
Authority
ES
Spain
Prior art keywords
polypeptide
immunity inducing
agent
inducing agent
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14185710.2T
Other languages
English (en)
Spanish (es)
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2619322T3 publication Critical patent/ES2619322T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES14185710.2T 2008-08-05 2009-08-05 Agente inductor de inmunidad Active ES2619322T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008202065 2008-08-05
JP2008202065 2008-08-05

Publications (1)

Publication Number Publication Date
ES2619322T3 true ES2619322T3 (es) 2017-06-26

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14185710.2T Active ES2619322T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad
ES09805008.1T Active ES2539603T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09805008.1T Active ES2539603T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad

Country Status (16)

Country Link
US (2) US8454968B2 (Direct)
EP (2) EP2324842B1 (Direct)
JP (2) JP5691171B2 (Direct)
KR (3) KR20160127146A (Direct)
CN (2) CN103751771B (Direct)
AU (2) AU2009278385B2 (Direct)
BR (2) BRPI0912462B1 (Direct)
CA (1) CA2732283C (Direct)
DK (2) DK2837383T3 (Direct)
ES (2) ES2619322T3 (Direct)
HU (1) HUE031343T2 (Direct)
MX (2) MX348464B (Direct)
PL (2) PL2837383T3 (Direct)
PT (2) PT2324842E (Direct)
RU (2) RU2511039C2 (Direct)
WO (1) WO2010016525A1 (Direct)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2733492T3 (pl) 2008-08-05 2016-08-31 Toray Industries Sposób wykrywania nowotworów
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
WO2011096528A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US8828398B2 (en) 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532680T3 (pl) 2010-02-04 2015-10-30 Toray Industries Kompozycja medyczna do leczenia raka i/lub zapobiegania
PL2532367T3 (pl) * 2010-02-04 2019-02-28 Toray Industries, Inc. Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu
WO2011096533A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
PL2711017T3 (pl) * 2011-05-19 2017-01-31 Toray Industries, Inc. Środek indukujący odporność
CA2844034C (en) 2011-08-04 2019-07-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
PL2740489T3 (pl) 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
US9175074B2 (en) 2011-08-04 2015-11-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
AU2012290948B2 (en) 2011-08-04 2017-05-25 Toray Industries, Inc. Method for detecting pancreatic cancer
MX348579B (es) * 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CN103717737B (zh) * 2011-08-04 2015-06-10 东丽株式会社 癌的治疗和/或预防用药物组合物
AU2013223137B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
AU2013223161B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
EP2824114B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
WO2013147169A1 (ja) * 2012-03-30 2013-10-03 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
RU2649802C2 (ru) 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
AU2013291047B2 (en) 2012-07-19 2018-12-06 Toray Industries, Inc. Cancer detection method
DK2876447T3 (da) 2012-07-19 2020-02-24 Toray Industries Fremgangsmåde til detektering af cancer
DK3031826T3 (en) 2013-08-09 2018-12-17 Toray Industries Pharmaceutical composition for the treatment and / or prevention of cancer
MX390696B (es) * 2015-04-30 2025-03-21 Toray Industries Agente inductor de inmunidad.
KR20240005247A (ko) * 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US20210121562A1 (en) * 2018-03-30 2021-04-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US8211634B2 (en) * 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
US20140357512A1 (en) * 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma

Also Published As

Publication number Publication date
EP2324842B1 (en) 2015-03-25
HUE031343T2 (hu) 2017-07-28
AU2015210461B2 (en) 2017-07-13
JP2015061847A (ja) 2015-04-02
KR20160127146A (ko) 2016-11-02
RU2011108315A (ru) 2012-09-10
JP5962739B2 (ja) 2016-08-03
PL2324842T3 (pl) 2015-08-31
CN102112146A (zh) 2011-06-29
US20130230488A1 (en) 2013-09-05
US20110123492A1 (en) 2011-05-26
US9592281B2 (en) 2017-03-14
AU2009278385A1 (en) 2010-02-11
EP2837383B1 (en) 2016-12-14
CN103751771B (zh) 2017-09-08
BR122020027042B1 (pt) 2022-11-08
ES2539603T3 (es) 2015-07-02
CN103751771A (zh) 2014-04-30
MX339277B (es) 2016-05-19
PT2324842E (pt) 2015-07-21
BRPI0912462B1 (pt) 2022-03-22
KR20110044854A (ko) 2011-05-02
KR101669827B1 (ko) 2016-10-27
EP2837383A1 (en) 2015-02-18
EP2324842A4 (en) 2012-05-23
AU2009278385B2 (en) 2015-06-11
AU2015210461A1 (en) 2015-09-03
MX2011001113A (es) 2011-03-04
PL2837383T3 (pl) 2017-07-31
KR102009241B1 (ko) 2019-08-09
RU2639518C2 (ru) 2017-12-21
EP2324842A1 (en) 2011-05-25
DK2324842T3 (da) 2015-06-22
DK2837383T3 (en) 2017-03-20
RU2511039C2 (ru) 2014-04-10
WO2010016525A1 (ja) 2010-02-11
RU2013156620A (ru) 2015-06-27
JP5691171B2 (ja) 2015-04-01
PT2837383T (pt) 2017-03-17
BRPI0912462A2 (Direct) 2016-02-02
CA2732283C (en) 2017-12-05
KR20170128637A (ko) 2017-11-22
CN102112146B (zh) 2014-03-12
US8454968B2 (en) 2013-06-04
MX348464B (es) 2017-06-14
CA2732283A1 (en) 2010-02-11
JPWO2010016525A1 (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
ES2619322T3 (es) Agente inductor de inmunidad
ES2541217T3 (es) Diferenciación de células madre mesenquimales
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
ES2512141T3 (es) Análogo peptídico de oxintomodulina
MX2017013122A (es) Metodos de reparacion y regeneracion tisular.
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
AR080658A1 (es) Toxinas insecticidas cry dig-5 de bacillus thuringiensis
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
CR20150196A (es) Moléculas de unión il-17a novedosas y usos médicos de las mismas
ES2524251T3 (es) Proteínas de tipo interferón humano recombinantes
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
MX390157B (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2536238T3 (es) Péptidos antimicrobianos
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
ES2605171T3 (es) Composiciones ansiolíticas que comprenden péptidos derivados de la Caseína ALFAs1